The Sage Group

According to THE SAGE GROUP, Restenosis Remains a Significant and Costly Problem After Endovascular Treatment of Peripheral Artery Disease (PAD)

BEAUFORT, SC, March 16, 2021 (BUSINESS WIRE)—Recent research published by THE SAGE GROUP examined the incidence and cost of restenosis in femoropopliteal disease.

“The cost of restenosis after treatment with percutaneous transluminal angioplasty (PTA) is $364-$728 million,” stated Mary L. Yost, President of THE SAGE GROUP. “New technologies, drug-coated balloons (DCBs) and drug-eluting stents (DES), have decreased restenosis and reduced longer-term revascularization costs.”

“Reflecting higher-priced devices, initial treatment with DCBs and DES costs more. However, with fewer reinterventions, DCB are the most cost-effective treatment followed by DES,” Yost explained.

Yost elaborated on significant factors that affect economic outcomes, “Bailout stenting increases costs in DCB interventions, adding approximately $2,200 to initial procedure costs. The total cost impact depends on the percentage of bailout stenting required. While some studies showed stenting rates below 20%, others found much higher rates of 40% to 60%. Since costs are a key variable in cost-effectiveness analyses, higher bailout stenting rates with DCB procedures adversely impact economic outcomes.”

“Even with the availability of new drug-coated devices, restenosis remains a major, costly problem,” Ms. Yost stated. “This reflects the fact that restenosis is higher in real-world patients than in the populations studied in DCB and DES clinical trials and registries.”

“Approximately, 80% of patients do not meet U.S. clinical device trial inclusion criteria. Consequently, PAD patients with severe critical limb ischemia (CLI) are commonly excluded, as are those with a high percentage of TASC C and D lesions, long total occlusions, severe calcification, extensive popliteal vessel involvement and no runoff vessels.,” Yost explained. “These are all factors that increase the risk of restenosis.”

About the Report: Femoropopliteal Disease: Incidence of Restenosis After Endovascular Revascularization and Review of Cost-Effectiveness Analyses

The report focuses on endovascular treatment of femoropopliteal disease. Incidence of restenosis (CD-TLR) is reviewed by device (PTA, BMS, DES and DCB) for clinical trials and registries. Restenosis is also assessed for real-world patients, long lesions and by disease severity.

Cost-effectiveness studies in the U.S., Germany and the UK are reviewed and analyzed.

Additional information:

THE SAGE GROUP, a research and consulting company, specializes in PAD, Intermittent Claudication (IC), CLI and chronic venous disease.

Additional information:


Mary Yost, (404) 520-6652